Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + Carboplatin + Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT05965141Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of eribulin in ovarian cancer, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Status: unknown.
02
Drugs
eribulin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05965141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965141.